The impact of the COVID-19 pandemic on Antipsychotic Prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: A federated analysis of 59 million patients primary care records in situ using OpenSAFELY
Macdonald, O.; Green, A.; Walker, A. J.; Croker, R.; Curtis, H. J.; Brown, A.; Butler-Cole, B.; Andrews, C.; Morton, C. E.; Evans, D.; Inglesby, P.; Dillingham, I.; Massey, J.; Fisher, L.; Bacon, S.; Davy, S.; Ward, T.; Hulme, W.; Morley, J.; Mehrkar, A.; Bates, C.; Cockburn, J.; Parry, J.; Hester, F.; Harper, S.; O'Hanlon, S.; Eavis, A.; Jarvis, R.; Avramov, D.; Wood, I.; Parkes, N.; Goldacre, B.; MacKenna, B.
Show abstract
BackgroundThe COVID-19 pandemic significantly affected health and social care services. We aimed to explore whether this impacted the prescribing rates of antipsychotics within at-risk populations. MethodsWith the approval of NHS England, we completed a retrospective cohort study, using the OpenSAFELY platform to explore primary care data of 59 million patients. We identified patients in five at-risk groups: autism, dementia, learning disability, serious mental illness and care home residents. We then calculated the monthly prevalence of antipsychotic prescribing in the population, as well as the incidence of new prescriptions in each month over the study period (Jan 2019-Dec 2021). ResultsThe average monthly rate of antipsychotic prescribing increased in dementia from 82.75 patients prescribed an antipsychotic per 1000 patients (95% CI 82.30-83.19) in Q1 2019 to 90.1 (95% CI 89.68-90.60) in Q4 2021 and from 154.61 (95% CI 153.79-155.43) in Q1 2019 to 166.95 (95% CI 166.23-167.67) in Q4 2021 in care homes. There were notable spikes in the rate of new prescriptions issued to patients with dementia and in care homes. In learning disability and autism groups, the average monthly rate of prescribing per 1000 decreased from 122.97 (95% CI 122.29-123.66) in Q1 2019 to 119.29 (95% CI 118.68-119.91) in Q4 2021, and from 54.91 (95% CI 54.52-55.29) in Q1 2019 to 51.04 (95% CI 50.74-51.35) in Q4 2021 respectively. ConclusionsDuring each of the lockdowns in 2020, we observed a significant spike in antipsychotic prescribing in the dementia and care home groups. We have shown that these peaks are likely due to prescribing of antipsychotics for palliative care purposes and may have been linked to pre-emptive prescribing, when on-site medical visits would have been restricted. Over the study period, we observed gradual increases in antipsychotic use in patients with dementia and in care homes and a decrease in their use in patients with learning disability or autism.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The impact of the COVID-19 pandemic on Antidepressant Prescribing with a focus on people with learning disability and autism: An interrupted time-series analysis in England using OpenSAFELY-TPP 96%
- Co-prescription of Metformin and Antipsychotics in Severe Mental Illness: A UK Primary Care Cohort Study 94%
- Using electronic health records to evaluate a children and young people's social prescribing service: Challenges and implications for research and practice 92%
Similar papers in this journal
- Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care: A 20-year investigation of who receives treatment, with which agents, and at what doses 95%
- Ethnic inequalities in compulsory psychiatric hospital detentions during UK COVID-19 'lockdowns': A Regression Discontinuity Design in time study 92%
- Analysis of diagnosis instability in electronic health records reveals diverse disease trajectories of severe mental illness 90%
Similar papers in this journal
- A qualitative exploration of barriers to efficient and effective Structured Medication Reviews in Primary Care: Findings from the DynAIRx study 93%
- Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia 92%
- Shared decision-making interventions in the choice of antipsychotic prescription in people living with psychosis (SHAPE): protocol for a realist review 91%
Similar papers in this journal
- Sativex (Nabiximols) for the treatment of Agitation & Aggression in Alzheimer’s Dementia in UK nursing homes (STAND): a randomised, double-blind, placebo-controlled feasibility trial 91%
- The consistent burden in published estimates of delirium occurrence in medical inpatients over four decades: a systematic review and meta-analysis study 89%
- COVID-19 risk factors amongst 14,786 care home residents: An observational longitudinal analysis including daily community positive test rates of COVID-19, hospital stays, and vaccination status in Wales (UK) between 1st September 2020 and 1st May 2021. 88%
Similar papers in this journal
- The Antidepressant Advisor (ADeSS): A Decision Support System for Antidepressant Treatment for Depression in UK primary care – a feasibility study 92%
- Study protocol for the development and internal validation of SPIRIT (Schizophrenia Prediction of Resistance to Treatment): A clinical tool for predicting risk of treatment resistance to anti-psychotics in First Episode Schizophrenia 92%
- How many medications do doctors in primary care use? An observational study of the DU90% indicator in primary care in England. 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.